Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -22,099
▲ 98% vs 2024
Profit
Caution€ -1.8 million
▲ 7% vs 2024
Debts
Normal€ 4.1 million
▲ 81% vs 2024
Swiftpharma from Genk, company number BE0781598284, closed financial year 2025 with a result of € -1.8 million after tax. For that financial year Swiftpharma recorded a gross margin of € -22,099 and equity of € 834,755. Compared with financial year 2024, the result moved from € -1.9 million to € -1.8 million. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.
What happened at Swiftpharma?
What happened at Swiftpharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1.8 million. Source: NBB ↗
- Bart Goddyn stepped down as director. NBB
- Bart Goddyn became a director. NBB
- JVHealth BV stepped down as director. NBB
- HofMan BV became a director. NBB
- Raymond Perrenet became a director. NBB
- New establishment in Genk. KBO
- Start of the company according to the CBE. KBO
In short
From € 57,060 profit in 2023 to € 1.8 million loss in 2025.
Paid € 5,401 in corporate taxes since 2023.
Best year ever: 2023, with € 57,060 profit.
On average € 331,200 of value added per employee in 2023.
A new publication or filing at Swiftpharma? We notify you, reason included.
Follow SwiftpharmaNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Swiftpharma are Raymond Perrenet and HofMan BV.
Directors
According to the 2025 annual accounts
Raymond Perrenet
Director
since 2024
Director · represented by Hofenk Jeroen
since 2024
since 2025 · until 2025
Director · represented by Van Havermaet Johan
since 2022 · until 2025
Establishments
Establishment units
Physical locations of this company
Thor Park 8027 box /0215
3600 Genk
Thor Park 8027 box 215
3600 Genk
Active since 4 February 2022
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
MACO
€ 1.1 million gross margin · 2025
Greensoil Group
€ 1.5 million gross margin · 2025
Hyve
€ 1.1 million gross margin · 2025
Boolean
€ 214,953 gross margin · 2025
VIMANPRO
€ 58,083 gross margin · 2025
+1 more
Details
- Company number
- 0781.598.284
- VAT number
- BE 0781.598.284
- Registered office
- Thor Park 8027 bus /0215, 3600 Genk
- Names & denominations
- Swiftpharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 February 2022
- Peppol
- Active · Active since 27 Feb 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Markt- en opinieonderzoek
Vervaardiging van farmaceutische grondstoffen